Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study. // Cytotherapy. – URL: https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all
Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study. Cytotherapy. https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all
“Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study.” Cytotherapy.
@article{article88966,
title = {Safety, efficacy, and PK/PD of a BCMA-targeted CAR-NK cell therapy (LUCAR-B68) in relapsed/refractory multiple myeloma: a phase I study},
journal = {Cytotherapy},
url = {https://www.sciencedirect.com/science/article/pii/S146532492600993X?dgcid=rss_sd_all}
}